Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07448922 Carboplatin Bone Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07448922 clinical trial report covering Carboplatin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07448038 Selnoflast Atherosclerosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07448038 clinical trial report covering Selnoflast, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20260775 Bevacizumab biosimilar (Chia-tai Tianqing) BRAF Mutation colorectal cancers Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
CTR20260775 clinical trial report covering Bevacizumab biosimilar (Chia-tai Tianqing), Phase 2, endpoints, sponsor, geography, readout timing and developme
Latest Hotspot
8 min read
NCT07450183 Cemiplimab-RWLC Resectable Lung Non-Small Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07450183 clinical trial report covering Cemiplimab-RWLC, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07450963 Cadonilimab Locally Advanced Cervical Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07450963 clinical trial report covering Cadonilimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07451795 Retlirafusp alfa Metastatic castration-resistant prostate cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07451795 clinical trial report covering Retlirafusp alfa, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07452250 Ferumoxytol Vein disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07452250 clinical trial report covering Ferumoxytol, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07450859 Nuzefatide pevedotin Metastatic Pancreatic Ductal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07450859 clinical trial report covering Nuzefatide pevedotin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07450976 SHR-A1904 Biliary Tract Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07450976 clinical trial report covering SHR-A1904, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07451652 Gemcitabine Hydrochloride Diffuse large B-cell lymphoma recurrent Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07451652 clinical trial report covering Gemcitabine Hydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07453069 FB-301 Vaginal flora imbalance Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07453069 clinical trial report covering FB-301, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07451886 Fludrocortisone Acetate Shock, Septic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07451886 clinical trial report covering Fludrocortisone Acetate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.